Legend Biotech Corp. (LEGN) PT Raised to $86 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
May 13, 2024 7:00 AM EDTCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma Legend and Johnson & Johnson enter into Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation On April 5, Legend Biotech earned a milestone payment of $45 million in connection with FDAs approval of CARVYKTIs label expansion to treat 2L+ MM, in accordance with the Janssen Agreement* Cash and cash equivalents, deposits, and short-term investments of $1.3... More
